Literature DB >> 25546198

18F-FLT PET imaging in a patient with sarcoidosis with cardiac involvement.

Takashi Norikane1, Yuka Yamamoto, Yukito Maeda, Takahisa Noma, Yoshihiro Nishiyama.   

Abstract

FDG PET has been proposed to play a role in the diagnosis and therapy monitoring of sarcoidosis including cardiac involvement. However, assessing inflammatory lesions in cardiac sarcoidosis using FDG can be challenging because the FDG accumulates in normal myocardium. We report a case of sarcoidosis with cardiac involvement that underwent 3'-deoxy-3'-F-fluorothymidine (FLT) PET. FLT PET images demonstrated increased uptake in the lymph nodes and left ventricle. After immunosuppressive therapy, a follow-up PET scan showed disappearance of FLT uptake in the lymph nodes and left ventricle.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25546198     DOI: 10.1097/RLU.0000000000000653

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  10 in total

1.  Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.

Authors:  Paco E Bravo; Amitoj Singh; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2018-11-02       Impact factor: 5.952

Review 2.  PET imaging in heart failure: the role of new tracers.

Authors:  Antti Saraste; Juhani Knuuti
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

Review 3.  The role of positron emission tomography in the assessment of cardiac sarcoidosis.

Authors:  Dario Genovesi; Matteo Bauckneht; Corinna Altini; Cristina Elena Popescu; Paola Ferro; Lavinia Monaco; Anna Borra; Cristina Ferrari; Federico Caobelli
Journal:  Br J Radiol       Date:  2019-06-05       Impact factor: 3.039

Review 4.  Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Authors:  Jakob Park; Bryan D Young; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2021-11-03       Impact factor: 3.872

Review 5.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity.

Authors:  David R Okada; Paco E Bravo; Tomas Vita; Vikram Agarwal; Michael T Osborne; Viviany R Taqueti; Hicham Skali; Panithaya Chareonthaitawee; Sharmila Dorbala; Garrick Stewart; Marcelo Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2016-09-09       Impact factor: 5.952

Review 6.  Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation.

Authors:  Malte Kircher; Constantin Lapa
Journal:  Curr Cardiovasc Imaging Rep       Date:  2017-02-10

Review 7.  Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis.

Authors:  Alison L Wand; Jonathan Chrispin; Elie Saad; Monica Mukherjee; Allison G Hays; Nisha A Gilotra
Journal:  Front Cardiovasc Med       Date:  2022-01-27

8.  Fluorine-18 fluorodeoxyglucose positron emission tomography for cardiac sarcoidosis-is it time to consider a new radiotracer?

Authors:  Georgios Christopoulos; Panithaya Chareonthaitawee
Journal:  EJNMMI Res       Date:  2017-08-29       Impact factor: 3.138

9.  Comparative evaluation of 18F-FLT and 18F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis.

Authors:  Takashi Norikane; Yuka Yamamoto; Yukito Maeda; Takahisa Noma; Hiroaki Dobashi; Yoshihiro Nishiyama
Journal:  EJNMMI Res       Date:  2017-08-29       Impact factor: 3.138

10.  Radiopharmaceutical tracers for cardiac imaging.

Authors:  Osamu Manabe; Tatsuya Kikuchi; Arthur J H A Scholte; Mohammed El Mahdiui; Ryuichi Nishii; Ming-Rong Zhang; Eriko Suzuki; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2017-12-01       Impact factor: 5.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.